MedTrace Logo

M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis

NCT06907680 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-06

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the efficacy and safety of M-Gard supplementation for alleviating the symptoms of allergic rhinitis.

Conditions

  • Allergic Rhinitis Due to Grass Pollens

Interventions

DIETARY_SUPPLEMENT

M-Gard

One capsule containing 250mg of M-Gard Particulate EW is taken twice daily for 14 days.

OTHER

Placebo

One capsule containing 250mg of MCC (Microcrystalline Cellulose) is taken twice daily for 14 days.

Sponsors & Collaborators

  • Lallemand Bio-Ingredients

    collaborator OTHER

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Thomas Tompkins · Lallemand Bio-Ingredients

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2026-01-29
Completion
2026-01-29

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06907680 on ClinicalTrials.gov